Pharma Focus Asia

Ardena Invests US$25 million (€20 million) to Expand New Facility in Belgium, Europe

Introduction:

Ardena plans to invest US$25 million (€20 million) to expand its new analytical laboratories in its expanded nanomedicines facility.

Features: 

The addition of the new 2,200m2 space, strategically positioned adjacent to current 4,000 square metres facilities, will result in a more than 50 percent expansion of the total site footprint.

The facility is equipped with advanced GMP-compliant cleanrooms, designed to bolster Ardena’s expanding nanomedicines division. 

Additionally, it houses laboratories dedicated to process development and analytical tasks, GMP production areas, and warehouse amenities.

With this increased capacity, the facility is fully prepared to drive forward the progress of nanomedicine research and development, expedite the creation and production of revolutionary nanomedicine drugs, efficiently translate novel therapies from idaea to clinical implementation, and ultimately, deliver benefits to patients globally.

The facility is now operational for process development and GMP analytical tasks. Furthermore, the acquisition of the GMP licence for the new production facility is anticipated in the coming months, allowing for complete operational functionality.

Specifications:

Name       Ardena
Type        Expansion
Budget   US$25 million (€20 million)


 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference